RBC Capital Reiterates Sector Perform on Biomarin Pharmaceutical, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated a Sector Perform rating for Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a price target of $100.
September 05, 2024 | 3:56 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has reiterated its Sector Perform rating for Biomarin Pharmaceutical, maintaining a $100 price target. This suggests a neutral outlook on the stock's performance.
The reiteration of a Sector Perform rating and maintenance of a $100 price target by RBC Capital indicates a neutral stance on Biomarin's stock. This suggests that the analyst does not expect significant short-term price movement, either up or down.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100